Bavarian Nordic Enters License and Manufacturing Agreement for its Mpox Vaccine with Serum Institute of India
Tech transfer of MVA-BN® will help increase global mpox vaccine manufacturing capacity…
New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic
COPENHAGEN, Denmark, December 13, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced…
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise
COPENHAGEN, Denmark, November 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced…
Bavarian Nordic Announces Interim Results for the First Nine Months of 2024
COPENHAGEN, Denmark, November 15, 2024 – Bavarian Nordic A/S (OMX: BAVA) announced…
Nordic Bioscience receives Letter of Support from the FDA for the CPa9-HNE biomarker in inflammatory bowel diseases
HERLEV, Denmark, Nov. 11, 2024 /PRNewswire/ -- Nordic Bioscience, a leading biomarker company,…
